# Medigene

MDG1015 is a first-in-class, third-generation TCR construct, with the company's broader pipeline (MDG3020, MDG3010) extending its TCR platform.

Source: https://en.bioecon.ru/companies/medigene/
Updated: 2026-07-11

- Country: Germany
- Ticker: MDG

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Raised EUR 5.9 million in May 2024; secured a standby equity purchase agreement for up to EUR 15 million in October 2024 | https://medigene.com/medigene-ag-extends-cash-runway-into-july-2025-after-successful-oversubscribed-capital-raise/, https://medigene.com/medigene-ag-reports-financial-results-and-business-update-for-q3-2024/, https://www.biospace.com/press-releases/medigene-ag-reports-financial-results-and-business-update-for-q3-2024 |
| Capacity | Six-day manufacturing process developed for TCR-T therapies, producing an almost pure CD8+ population with ~95% stem-like qualities [medium confidence] | https://synapse.patsnap.com/article/medigene-unveils-6-day-efficient-tcr-t-therapy-production-with-high-stemness |
| Certification | No specific ISO or manufacturing certifications mentioned; holds patents for lead program MDG1015 components | https://medigene.com/medigene-ag-reports-financial-results-and-business-update-for-q3-2024/ |
| Regulatory approval | FDA IND clearance received in Q3 2024 for MDG1015; CTA submission to EMA in Q4 2024 | https://medigene.com/medigene-ag-reports-financial-results-and-business-update-for-q3-2024/, https://medigene.com/medigene-ag-submits-clinical-trial-application-in-europe-for-mdg1015-for-multiple-solid-tumor-indications/, https://medigene.com/medigene-announces-u-s-fda-clearance-of-ind-application-for-mdg1015-for-multiple-solid-tumor-indications/ |
| Production site | Located at Lochhamer Strasse 11, 82152 Martinsried, Germany | https://www.marketscreener.com/quote/stock/MEDIGENE-AG-14120225/company/ |
| Revenue | EUR 1.4 million in Q3 2024; trailing 12-month revenue of $8.06 million as of June 30, 2024 | https://medigene.com/medigene-ag-reports-financial-results-and-business-update-for-q3-2024/ |

Independent sources: biospace.com, marketscreener.com, synapse.patsnap.com

## Technologies

- [TCR therapy (T-cell receptor engineered T cells)](https://en.bioecon.ru/technology/tcr-therapy/)